302 related articles for article (PubMed ID: 30670682)
21. SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents.
Amir S; Mabjeesh NJ
Cancer Biol Ther; 2007 Dec; 6(12):1926-31. PubMed ID: 18075300
[TBL] [Abstract][Full Text] [Related]
22. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
23. SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation.
Zeng Y; Cao Y; Liu L; Zhao J; Zhang T; Xiao L; Jia M; Tian Q; Yu H; Chen S; Cai Y
Cell Death Dis; 2019 Sep; 10(10):720. PubMed ID: 31558699
[TBL] [Abstract][Full Text] [Related]
24. Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid.
Yin S; Cabral F; Veeraraghavan S
Mol Cancer Ther; 2007 Oct; 6(10):2798-806. PubMed ID: 17938271
[TBL] [Abstract][Full Text] [Related]
25. Nordihydroguaiaretic acid, of a new family of microtubule-stabilizing agents, shows effects differentiated from paclitaxel.
Nakamura M; Nakazawa J; Usui T; Osada H; Kono Y; Takatsuki A
Biosci Biotechnol Biochem; 2003 Jan; 67(1):151-7. PubMed ID: 12619686
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Ling YH; Jiang JD; Holland JF; Perez-Soler R
Mol Pharmacol; 2002 Sep; 62(3):529-38. PubMed ID: 12181429
[TBL] [Abstract][Full Text] [Related]
27. Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments.
Verdier-Pinard P; Salaun D; Bouguenina H; Shimada S; Pophillat M; Audebert S; Agavnian E; Coslet S; Charafe-Jauffret E; Tachibana T; Badache A
Sci Rep; 2017 Mar; 7():44976. PubMed ID: 28338090
[TBL] [Abstract][Full Text] [Related]
28. In vivo measurement of microtubule dynamics using stable isotope labeling with heavy water. Effect of taxanes.
Fanara P; Turner S; Busch R; Killion S; Awada M; Turner H; Mahsut A; Laprade KL; Stark JM; Hellerstein MK
J Biol Chem; 2004 Nov; 279(48):49940-7. PubMed ID: 15385549
[TBL] [Abstract][Full Text] [Related]
29. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.
Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C
Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942
[TBL] [Abstract][Full Text] [Related]
30. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
31. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
32. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Mukhtar E; Adhami VM; Sechi M; Mukhtar H
Cancer Lett; 2015 Oct; 367(2):173-83. PubMed ID: 26235140
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
34. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously.
Gapud EJ; Bai R; Ghosh AK; Hamel E
Mol Pharmacol; 2004 Jul; 66(1):113-21. PubMed ID: 15213302
[TBL] [Abstract][Full Text] [Related]
35. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.
Ranganathan S; Benetatos CA; Colarusso PJ; Dexter DW; Hudes GR
Br J Cancer; 1998 Feb; 77(4):562-6. PubMed ID: 9484812
[TBL] [Abstract][Full Text] [Related]
36. Microtubules and resistance to tubulin-binding agents.
Kavallaris M
Nat Rev Cancer; 2010 Mar; 10(3):194-204. PubMed ID: 20147901
[TBL] [Abstract][Full Text] [Related]
37. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
[TBL] [Abstract][Full Text] [Related]
38. Human mutations that confer paclitaxel resistance.
Yin S; Bhattacharya R; Cabral F
Mol Cancer Ther; 2010 Feb; 9(2):327-35. PubMed ID: 20103599
[TBL] [Abstract][Full Text] [Related]
39. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
[TBL] [Abstract][Full Text] [Related]
40. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
Wang Y; O'Brate A; Zhou W; Giannakakou P
Cell Cycle; 2005 Dec; 4(12):1847-53. PubMed ID: 16294009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
